Board of Directors

  • Robert (Bob) W. Duggan

    Chairman of the Board of Directors
    Robert W. Duggan has been a director and chairman of the Board of Directors since November 2017. From 2015 Mr. Duggan has been CEO of Duggan Investments, a venture capital and public equity investment firm. His venture investments primarily focus on patient-friendly break through solutions to complex diseases of aging. From 2008 to 2015, Mr. Duggan was Chairman, CEO and the largest investor in Pharmacyclics, a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of cancers. Pharmacyclics was sold to AbbVie for $21 billion in May of 2015. From 1990 to 2003, Mr. Duggan was Chairman of the Board of Computer Motion. From 1997 to 2003, Mr. Duggan also served as Chief Executive officer of Computer Motion. In June of 2003, Computer Motion merged with Intuitive Surgical [NASDAQ:ISRG]. This culminated in Computer Motion shareholders owning a 1/3 interest in the resulting business. From 2003 to 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical. Mr. Duggan received a U.S. Congressman's Medal of Merit from Ron Paul in 1985 and in 2000 he was named a Knight of the Legion D’Honor by President Jacques Chirac of France. He is a member of the University of California at Santa Barbara Foundation Board of Trustees. Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences as well as a Chair in Religious studies at the University of California at Santa Barbara.
  • Darrin R. Uecker

    Chief Executive Officer, President & Director
    Darrin R. Uecker has been our Chief Executive Officer and President and a Director since September 2015. Mr. Uecker has over 20 years of experience in the medical device field and is a named inventor on over 60 patents. Prior to Pulse Biosciences Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., Menlo Park, California, a company that developed EevaTM, the world’s first automated time-lapse system for embryo selection during in-vitro fertilization. Prior to that Mr. Uecker was the Chief Executive Officer and President and a Director of Gynesonics, Inc., Redwood City, California, a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radio frequency ablation. Mr. Uecker has served in a variety of executive level roles at CyperHeart, Inc., Conceptus, Inc., RITA Medical Systems, Inc., and Computer Motion, Inc. Mr. Uecker attended the University of California at Santa Barbara where he received a B.S. and M.S. in electrical and computer engineering.
    • Kenneth A. Clark

      Kenneth A. Clark has been a director since November 2017. Mr. Clark has been a member of the law firm Wilson Sonsini Goodrich & Rosati, P.C. since 1993. His practice has focused on strategic transactions in the biopharmaceutical industry for over 25 years. Mr. Clark served on the board of directors of Pharmacyclics, Inc., from November 2012 through the acquisition by AbbVie in May 2015. He holds a B.A. degree from Vanderbilt University and a law degree from the University of Texas at Austin.
    • Thomas J. Fogarty, MD

      Thomas J. Fogarty, M.D. has served as a director since November 2017. Dr. Fogarty has been involved with a wide spectrum of innovations in business and technology, having served as founder/co-founder of a variety of companies, and acquired over 160 surgical patents. Dr. Fogarty received the National Medal of Technology and Innovation, the nation’s highest honor for technological achievement, in November 2014, the Jacobson Innovation Award of the American College of Surgeons, the 2000 Lemelson-MIT prize for Invention and Innovation and was inducted into the Inventors Hall of Fame in December 2001. Dr. Fogarty founded the Fogarty Institute for Innovation at El Camino Hospital, which seeks to create an environment where innovation in medicine is encouraged, supported, and nurtured. Dr. Fogarty received his undergraduate education at Xavier University and his medical degree from the University of Cincinnati. He completed his residency at the University of Oregon and later served as Medical Staff President at Stanford Medical Center from 1973-1975.
    • Mitchell E. Levinson

      Mitchell E. Levinson has been a member of our Board of Directors since March 2019 and had previously served as a board member from January 2015 to November 2017.  Mr.  Levinson is currently a board member and Chief Technology Officer of Cerebrotech, an innovative neurotechnology device company focused on the development of portable neurotechnology solutions, that he co-founded during 2010.   Prior to 2010, Mr. Levinson was the start-up CEO for Zeltiq Aesthetics Inc. when he became its first employee in 2005, and served as its president and its Chief Executive Officer from September 2005 until September 2009.  He continued with Zeltiq as Chief Scientific Officer from September 2009 through December 2010.  From March 2000 to September 2005 he served as Vice President of Research and Development of Thermage, Inc. (later renamed Solta Medical), a company engaged in cosmetic tissue tightening devices.  He is the inventor of 45 issued and numerous pending U.S. patents.  Mr. Levinson earned his BS in Mechanical Engineering from University of California at San Diego and holds an M.S in Computer Systems from the University of Phoenix.  Mr. Levinson was appointed as a director because he has over 25 years of progressive experience in product development and manufacturing engineering and he has many years of experience in medical device intellectual property, operations, clinical and regulatory strategy, commercial business development, sales training and marketing.
    • Manmeet S. Soni

      Manmeet S. Soni was appointed to our Board of Directors in November 2017. Mr. Soni has been the Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals since May 2017. From March 2016 to February 2017, Mr. Soni served as Chief Financial Officer and Treasurer of biopharmaceutical company ARIAD Pharmaceuticals, Inc., where he played a central role in the strategic review, turnaround, and subsequent acquisition of ARIAD Pharmaceuticals, Inc. by Takeda Pharmaceutical Company Limited. Before joining ARIAD Pharmaceuticals, Inc., Mr. Soni joined Pharmacyclics, Inc. in 2012 as controller and held various other roles there until becoming Chief Financial Officer and Treasurer in February 2015. He also played a vital role in the acquisition of Pharmacyclics, Inc. by AbbVie, Inc. for $21 billion. Previously, Mr. Soni worked at ZELTIQ Aesthetics Inc., and PricewaterhouseCoopers San Jose, in the Life Science and Venture Capital Group. Prior to that, he worked at PricewaterhouseCoopers India. Mr. Soni graduated from Hansraj College at Delhi University in India. He is recognized as a Certified Public Accountant, licensed by the State of California, and as a Chartered Accountant in India.
    • Mahkam "Maky" Zanganeh, DDS

      Mahkam “Maky” Zanganeh, D.D.S ,MBA , was appointed to our Board of Directors in February 2017. Dr. Zanganeh is currently Founder and CEO of Maky Zanganeh and Associates, an executive management and consulting firm. Previously, from August 2012 to September 2015, she served as the Chief Operating Officer of Pharmacyclics Inc., where she was instrumental in managing all the internal functions of the organization as well as closing several key deals for the company, including the strategic collaboration and licensing deal with Janssen Biotech, Inc. in 2011 and the sale of the company in 2015 to AbbVie for $21B. She was also served as Chief of Staff and Chief Business Officer of Pharmacyclics from December 2011 to July 2012 and Vice President, Business Development from August 2008 to November 2011. Prior to joining Pharmacyclics Inc., Dr. Zanganeh served as President Director General (2007-2008) for the French government bio-cluster project initiative in France, establishing alliances and developing small life science businesses regionally. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert W. Duggan & Associates. Dr. Zanganeh also served as worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle East and Africa (1998-2002) for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received a DDS degree from Louis Pasteur University in Strasbourg, France and MBA from Schiller International University in France.